Durvalumab plus anlotinib versus durvalumab alone as maintenance treatment in extensive-stage small-cell lung cancer (DURABLE): a multicenter, randomized, phase II trial and biomarker analysis

Journal:

Nature Communications

Published:

2026-05-25

DOI:

10.1038/s41467-026-73562-7

Affiliations:

6

Authors:

15

Go to article

Institutions	Authors	Share
Shanghai Chest Hospital, SJTU, China	9.000000	0.60
AmoyDx, China	2.000000	0.13
The First Affiliated Hospital of Nanchang University, China	1.000000	0.07
Anhui Provincial Cancer Hospital, China	1.000000	0.07
Shanxi Cancer Hospital, China	1.000000	0.07
Sichuan Cancer Hospital, China	1.000000	0.07

Interested in Oncology and Carcinogenesis?